Regular Article| Volume 95, ISSUE 7, P553-564, July 2001

The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia

      This paper is only available as a PDF. To read, Please Download here.


      An international multi-centre, randomized, prospective, double-blind study compared oral moxifloxacin (200 mg or 400 mg once daily for 10 days) with oral clarithromycin (500 mg, twice daily for 10 days) in the treatment of community-acquired pneumonia (CAP).
      The clinical success rate in the evaluable population at the primary efficacy assessment, 3–5 days after the end of study treatment, was 93·9% in patients treated with 200 mg moxifloxacin; 94·4%, with 400 mg moxifloxacin; and 94·3%, with clarithromycin. Clinical success rates were maintained at follow-up, 21–28 days after the end of treatment: 90·7% (200 mg moxifloxacin), 92·8% (400 mg moxifloxacin) and 92·2% (clarithromycin). The 95% confidence intervals indicated that all three treatment regimens were equally effective in treating CAP. At follow-up, the 400 mg moxifloxacin dose had a slightly higher observed cure rate than the 200 mg moxifloxacin dose, but this was not statistically significant.
      The most frequently isolated pathogens were Streptococcus pneumoniae (42%), Haemophilus influenzae (19%), Haemophilus parainfluenzae (10%), Moraxella catarrhalis (6%), Klebsiella pneumoniae (5%) andStaphylococcus aureus (4%). The bacteriological success rate (eradication and presumed eradication) was 72·5% (29/40) for 200 mg moxifloxacin, 78·7% (37/47) for 400 mg moxifloxacin and 70·7% (29/41) for clarithromycin.
      The adverse event profile was comparable between the three treatment groups. Most adverse events, possibly or probably related to the study drug, were generally mild or moderate in severity and mostly related to the digestive system: diarrhoea, nausea and abdominal pain in 200 mg moxifloxacin patients; diarrhoea, liver function abnormalities and nausea in 400 mg moxifloxacin patients and liver function abnormalities, diarrhoea, nausea and taste perversion in clarithromycin patients. Study drugs were discontinued because of adverse events in 7/229 (3%) patients treated with 200 mg moxifloxacin, 11/224 (5%) with moxifloxacin 400 mg and 11/222 (5%) with clarithromycin.
      In all assessments, moxifloxacin was at least as effective clinically, and as well tolerated as clarithromycin in the treatment of CAP. Bacteriological success rates in moxifloxacin-treated patients were greater than those of clarithromycin. Moxifloxacin, given once daily, is free of many drug–drug interactions and requires no dosage adjustments in most renal/hepatic deficient patients.




        • Finch R
        • Chow AW
        • Hall CB
        General guidelines for the evaluation of new anti-infective drugs for the treatment for respiratory tract infections.
        Eur Soc Clin Microbiol Infect Dis. 1993; : 93-98
        • Woodhead MA
        • MacFarlane JT
        • McCracken JS
        Prospective study of the aetiology and outcome of pneumonia in the community.
        Lancet. 1987; : 671-674
        • Wort SJ
        • Rogers TR
        Community acquired pneumonia in elderly people. Current British guidelines need revision.
        BMJ. 1998; 361: 1690
        • Bartlett JG
        • Breiman RF
        • Mandell LA
        • File TM
        Community-acquired pneumonia in adults: Guidelines for management.
        Clin Inf Dis. 1998; 26: 811-838
        • Huchon G
        • Woodhead M
        Management of adult community-acquired lower respiratory tract infection.
        Eur Respir Rev. 1998; : 391-425
        • Torres A
        • Serra Balles J
        • Ferrer A
        Severe community acquired pneumonia. Epidemiology and prognosis factors.
        Am Rev Respir Dis. 1991; 144: 311-318
      1. Br J Resp Med. 1993; 49: 346-350
        • Jacobs MR
        • Felmingham D
        • Applebaum PC
        The Alexander Project 1998: Penicillin and macrolide resistance in 2675 isolates of Streptococcus pneumoniae from 15 countries on five continents.
        Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, (ICAAC). 1999; : A-1044
        • Bartlett JG
        • Breiman RF
        • Mandell LA
        • File TM
        Guidelines from the Infectious Diseases Society of America. Community-acquired pneumonia in adults: guidelines for management.
        Clin Infect Dis. 1998; 26: 811-838
        • Greenberg RN
        Overview of patient compliance with medication dosing: a literature review.
        Clin Ther. 1994; 6: 592-599
        • Dalhoff A
        • Petersen U
        • Endermann R
        In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
        Chemotherapy. 1996; 42: 410-425
        • Bébéar CM
        • Renaudin H
        • Boudjadja A
        • Bébéar C
        In vitro activity of BAY 12-8039, a new fluoroquinolone against mycoplasmas.
        Antimicrob Agents Chemother. 1998; 42: 703-704
        • Roblin PM
        • Hammerschlag MR
        In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.
        Antimicrob Agents Chemother. 1998; 42: 951-952
        • Dalhoff A
        Moxifloxacin — review of microbiology. Activity against M. catarrhalis and atypicals.
        Congress New Quinolones. 1998;
        • Soman A
        • Honeybourne D
        • Andrews J
        • Jevons G
        • Wise R
        Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg dose in patients undergoing fibre-optic bronchoscopy.
        JAC. 2000; 44: 835-838
      2. CPMP. 1990;
        • Ball P
        • Mandell L
        • Niki Y
        • Tillotson G
        Comparative tolerability of the newer flouroquinolones.
        Drug Safety. 1999; 21: 407-421
        • Baquero F
        Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption?.
        J Chemother. 1999; 11: 35-43
        • Bauernfeind A
        Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levoflaxacin and ciprofloxacin.
        J Antimicrob Chemother. 1997; 40: 639-651
        • Blondeau JM
        • Suter M
        • Borsos S
        Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae,Streptococcus pneumoniae and Moraxella catarrhalis.
        J Antimicrob Chemother. 1999; 43: 25-30
        • Klugman KP
        • Capper T
        Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin.
        J Antimicrob Chemother. 1997; 40: 797-802
        • Dalhoff A
        • Preuss I
        Moxifloxacin—distribution of MICs against European isolates of S. pneumoniae, M. catarrhalis and H. influenzae.
        Moxifloxacin Posters presented at the 21stInternational Congress of Chemotherapy. 1999;
        • Bamarouf AO
        • Amyes S GB
        • Thompson CJ
        Activity of Moxifloxacin and other new quinolones against genetically characterised penicillin-resistantStreptococcus pneumoniae clinical isolates from the UK.
        J Antimicrob Chemother. 1999; 44: 407
        • Patel T
        • Williams J
        • Haverstock D
        • Church D
        Efficacy and safety of moxifloxacin for the treatment of community acquired pneumonia.
        Respir Med. 2000; 94: 97-105
        • Fogarty C
        • Grossman C
        • Williams J
        • Haverstock D
        • Church D
        Efficacy and safety of moxifloxacin vs clarithromycin for community-aquired pneumonia.
        Infect Med. 1999; 16: 748-763
      3. Petitpretz, P, Arvis, P, Marel, M, Moita, J, Urueta, J, CAP5 Moxifloxacin Study Group, Oral moxifloxacin vs high dose amoxicillin in the treatment of non-severe, community-acquired, suspected pneumococcal pneumonia in adults

        • Springsklee M
        Clinical needs in the millenium-pneumonia-the role of moxifloxacin.
        in: Mandell L First International Moxifloxacin Symposium, Berlin 1999. Springer-Verlag, Heidelberg1999
      4. Campbell, D. Tillotson, G, The treatment of community-acquired pneumonia with fluoroquinolones, 2000

        • Stass H
        • Kubitza D
        Basic pharmaocokinetics of moxifloxacin.
        Drugs. 1999; 58: 225-226
      5. Stass, H, Kern, A, Metabolism and excretion of moxifloxacin, Drugs

      6. Dalhoff, A, Dissociated resistance among flouroquinolones, First International Moxifloxacin Symposium, Berlin, 1999

        • Guillemot D
        • Carbon C
        • Balkau B
        Low dosage and long treatment duration of ß-lactam: Risk factors for carriage of penicillin-resistantStreptococcus pneumoniae.
        JAMA. 1998; 279: 365-370
        • Struelens MJ
        The epidemiology of antimicrobial resistance in hospital acquired infections: Problems and possible solutions.
        BMJ. 1998; 317: 652-654